We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

115 hedge funds and large institutions have $757M invested in Avidity Biosciences in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,100% more call options, than puts

Call options by funds: $3.46M | Put options by funds: $2K

280% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 5

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

12% more funds holding

Funds holding: 103 → 115 (+12)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.12% less ownership

Funds ownership: 106.91% → 104.79% (-2.1%)

30% less capital invested

Capital invested by funds: $1.09B → $757M (-$328M)

Holders
115
Holders Change
+12
Holders Change %
+11.65%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
44
Reduced
19
Closed
5
Calls
$3.46M
Puts
$2K
Net Calls
+$3.46M
Net Calls Change
+$747K

Top Buyers

1
CAC
Cowen and Company
New York
+$33.7M
2
BlackRock
BlackRock
New York
+$9.9M
3
Artisan Partners
Artisan Partners
Wisconsin
+$5.85M
4
State Street
State Street
Massachusetts
+$2.91M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.78M

Top Sellers

1
AWA
Aaron Wealth Advisors
Illinois
-$56.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.52M
3
ACM
Altium Capital Management
New York
-$1.38M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$1M
5
ACM
Alethea Capital Management
Washington
-$811K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$115M -$1.52M -102,410 -1%
RI
2
RTW Investments
New York
$69.7M – – –
BlackRock
3
BlackRock
New York
$57.1M +$9.9M +665,653 +20%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$55.3M -$26.7K -1,792 -0%
EC
5
EcoR1 Capital
California
$40.1M – – –
Federated Hermes
6
Federated Hermes
Pennsylvania
$36M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$35.2M +$1.84M +123,759 +5%
CAC
8
Cowen and Company
New York
$32.9M +$33.7M +2,264,150 New
RCM
9
RA Capital Management
Massachusetts
$31.5M – – –
APM
10
Avidity Partners Management
Texas
$30.2M +$524K +35,200 +2%
CAM
11
Cormorant Asset Management
Massachusetts
$29.2M – – –
State Street
12
State Street
Massachusetts
$26.7M +$2.91M +195,808 +12%
ACA
13
Avoro Capital Advisors
New York
$18.9M – – –
BC
14
Boxer Capital
California
$16.3M – – –
Wellington Management Group
15
Wellington Management Group
Massachusetts
$15.5M -$1M -67,521 -6%
Alkeon Capital Management
16
Alkeon Capital Management
New York
$12.4M – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$12.3M +$1.66M +111,605 +15%
ACM
18
Alethea Capital Management
Washington
$12.1M -$811K -54,484 -6%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$7.41M +$2.05M +137,519 +37%
GPP
20
Great Point Partners
Connecticut
$7.26M – – –
Northern Trust
21
Northern Trust
Illinois
$6.64M +$1.24M +83,520 +22%
Artisan Partners
22
Artisan Partners
Wisconsin
$5.71M +$5.85M +393,341 New
5VM
23
5AM Venture Management
California
$5.67M – – –
Charles Schwab
24
Charles Schwab
California
$4.9M +$561K +37,677 +13%
OCA
25
Octagon Capital Advisors
New York
$4.67M – – –
1
2 3 4 5

RNAM Hedge Fund Activity: Q2 2022 in Review

115 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2022, worth a combined $757M — down 30% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RNAM positions and 5 closed out — a net gain of 14 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $33.7M. The largest seller was Aaron Wealth Advisors, cutting an estimated $56.1M.

  • 115 institutional investors held Avidity Biosciences (RNAM) as of Q2 2022, up from 103 in Q1 2022.
  • Funds reported $757M of Avidity Biosciences stock for Q2 2022, down 30% quarter-over-quarter.
  • 19 funds opened new Avidity Biosciences positions in Q2 2022 and 5 closed out, a net change of +14 holders.
  • The largest Avidity Biosciences buyer in Q2 2022 was Cowen and Company, an estimated $33.7M added.
  • The largest Avidity Biosciences seller in Q2 2022 was Aaron Wealth Advisors, an estimated $56.1M sold.

Based on aggregated 13F filings for Q2 2022.